Literature DB >> 11442637

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

I Scharrer1, H J Ehrlich.   

Abstract

De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11442637     DOI： 10.1046/j.1365-2516.2001.00515.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  3 in total

1.  Factor VIII inhibitor and source of replacement therapy.

Authors:  Pier Mannuccio Mannucci; Alessandro Gringeri; Elena Santagostino; Flora Peyvandi
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

Review 2.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

3.  Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII.

Authors:  Marcela Cristina Correa de Freitas; Aparecida Maria Fontes; Andrielle de Castilho Fernandes; Virginia Picanço-Castro; Elisa Maria de Sousa Russo; Dimas Tadeu Covas
Journal:  Rev Bras Hematol Hemoter       Date:  2014-04-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.